Efavirenz
Alternative Names: DMP 266; L 741211; L 743725; L 743726; Stocrin; SustivaLatest Information Update: 05 Nov 2023
At a glance
- Originator Merck & Co
- Developer Bristol-Myers Squibb
- Class Alkynes; Antiretrovirals; Benzoxazines; Cyclopropanes; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV-1 infections